Member Info for Sisyphus

And another whopping uncrossing trade today. That's £0.75m yesterday and £0.88m today. Things are shaping up as the few shorters bail out.

BioMerieux SA and Illumina could both be interested enough to secure control here. That would certainly perk up wider interest. Undervalued significantly imo given huge potential and fact that bioMerieux SA payed twice this price per share for its c 7%.

This little holding could have interesting significance also from June 6th. Very undervalued and ideal tech for big pharma.

Nice tidy £0.75m uncrossing trade there.

Hi Roofer, 74.6 please.

In a trading channel. Just needs volume to reverse it and break that ceiling. Love to see it before 15th May or it could be the update that triggers it. Patience is always tested when multiple attempts fail prior to the volume that is needed to produce the momentum to breach previous peak.

Delayed but starting.....frustrating.

Reversal now and a push to that 71.2.....let's have the bot volume.

Eyes on 9 and volume....

With a decent days trading this could finally break through the last peak and close above 71.2 but we need volume to maintain momentum. Good start?

Fair list of entrants emerging. Didn't breach my 71.6 this week but I think the glass ceiling will go next week before 15th May announcement. So 74.2 for me - cheers.

Agree. 70 is a rubber ceiling at present but once it goes on volume 71.6 should be a hurdle then we're in bluesy for the next peak pre May 15th hopefully.

Would love to see it breach 71.6 in a reflex near-term move that would instil confidence.

71.6p for Friday Roofer

Given the fervor for 'all things American' and the fact that Kainos has a big footprint and significant revenue stream in the USA I'm surprised this hasn't soared already. Similar businesses over the water command a far higher p/e than here despite the constant comment that it's on the high side (for here!). Next week's update should reassure and set it firmly back on the ascent.

Pulls back am, rises pm. Stateside stakebuilding???

Looks like c £1m shorter lost his nerve and bought back in.

Entry into ICU market expands revenue potential.

The size and scope of Ondines Steriwave continues to grow given its undeniable reduction in environment acquired infections and their huge cost to Healthcare globally. It really is the gold standard as roll out continues to attract new users and surgeon chat confirms statistics.

I think the approval of Steriwave, after recent trials, into the NHS has now primed Ondine for takeover by a big provider with the size to scale it. Ondine has 7 applications for Steriwave in its sights and pending Ph3 approval into the USA market.

Hospital acquired infections cost the NHS a fortune.

SSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS. SSIs can cost up to £100,000 per patient, and the overall cost of HAIs to NHS England is over £2 billion a year.